drug · small molecule
DIFLUPREDNATE
Marketedupdated 3mo agoby Ocuvex Therapeutics Inc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 5 investigational indications.
targets
Glucocorticoid receptor
all catalysts(11)
approval · 11
Jun 23, 2008
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Mar 20, 2009
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Jun 13, 2012
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Nov 27, 2012
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Mar 22, 2013
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
May 15, 2013
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Apr 11, 2016
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Jul 29, 2016
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Jul 15, 2025
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Oct 27, 2025
approval
DUREZOL (DIFLUPREDNATE) — FDA approval
DIFLUPREDNATE
→
Jan 26, 2026
approval
DIFLUPREDNATE — FDA approval
DIFLUPREDNATE
→
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that